A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer by Cameron, Simon et al.
Aberystwyth University
A pilot study using metagenomic sequencing of the sputum microbiome
suggests potential bacterial biomarkers for lung cancer
Cameron, Simon; Lewis, Keir E.; Huws, Sharon; Hegarty, Matthew; Lewis, Paul D.; Pachebat, Justin Alexander;
Mur, Luis
Published in:
PLoS One
DOI:
10.1371/journal.pone.0177062
Publication date:
2017
Citation for published version (APA):
Cameron, S., Lewis, K. E., Huws, S., Hegarty, M., Lewis, P. D., Pachebat, J. A., & Mur, L. (2017). A pilot study
using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung
cancer. PLoS One, [0177062]. https://doi.org/10.1371/journal.pone.0177062
Document License
CC BY
General rights
Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are
retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the
legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or
research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
tel: +44 1970 62 2400
email: is@aber.ac.uk
Download date: 03. Oct. 2019
RESEARCH ARTICLE
A pilot study using metagenomic sequencing
of the sputum microbiome suggests potential
bacterial biomarkers for lung cancer
Simon J. S. Cameron1, Keir E. Lewis2,3, Sharon A. Huws1, Matthew J. Hegarty1, Paul
D. Lewis3, Justin A. Pachebat1, Luis A. J. Mur1*
1 Institute of Biological, Environmental and Rural Sciences, Edward Llywd Building, Penglais Campus,
Aberystwyth, Ceredigion, United Kingdom, 2 Department of Respiratory Medicine, Prince Phillip Hospital,
Hywel Dda University Health Board, Llanelli, United Kingdom, 3 College of Medicine, Swansea University,
Swansea, United Kingdom
* lum@aber.ac.uk
Abstract
Lung cancer (LC) is the most prevalent cancer worldwide, and responsible for over 1.3 mil-
lion deaths each year. Currently, LC has a low five year survival rates relative to other can-
cers, and thus, novel methods to screen for and diagnose malignancies are necessary to
improve patient outcomes. Here, we report on a pilot-sized study to evaluate the potential of
the sputum microbiome as a source of non-invasive bacterial biomarkers for lung cancer
status and stage. Spontaneous sputum samples were collected from ten patients referred
with possible LC, of which four were eventually diagnosed with LC (LC+), and six had no LC
after one year (LC-). Of the seven bacterial species found in all samples, Streptococcus viri-
dans was significantly higher in LC+ samples. Seven further bacterial species were found
only in LC-, and 16 were found only in samples from LC+. Additional taxonomic differences
were identified in regards to significant fold changes between LC+ and LC-cases, with five
species having significantly higher abundances in LC+, with Granulicatella adiacens show-
ing the highest level of abundance change. Functional differences, evident through signifi-
cant fold changes, included polyamine metabolism and iron siderophore receptors. G.
adiacens abundance was correlated with six other bacterial species, namely Enterococcus
sp. 130, Streptococcus intermedius, Escherichia coli, S. viridans, Acinetobacter junii, and
Streptococcus sp. 6, in LC+ samples only, which could also be related to LC stage. Sponta-
neous sputum appears to be a viable source of bacterial biomarkers which may have utility
as biomarkers for LC status and stage.
Introduction
Lung cancer is the most prevalent cancer in the world with 1.3 million deaths recorded each
year [1]. Lung cancers are classified into various subtypes reflecting their cytology and cellular
origins. The main sub-divisions are non-small-cell lung carcinoma (NSCLC) and small-cell
lung carcinoma (SCLC). The overall five year survival rate for lung cancer has improved very
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little over the last 30 years, with only 15% of patients living for five or more years after initial
diagnosis [2]. These poor survival rates are primarily due to its late detection, with two thirds
of patients diagnosed at a stage where chemotherapy and lung thoracotomy is less likely to be
successful [3].
The main risk factor for the development of lung cancer is tobacco smoking, but genetic
predisposition also plays a major role [4]; possibly explaining why not all smokers develop the
lung condition [5]. A history of previous lung disease such as chronic obstructive pulmonary
disease (COPD), chronic bronchitis, tuberculosis and pneumonia has been associated with an
increased risk of developing lung cancer [6]. Interestingly, in the “never smokers” group a sig-
nificantly increased risk of lung cancer was observed only in patients with a previous history of
pneumonia and tuberculosis. Such observations suggest that microbial changes–possibly
linked to inflammatory events–could be an independent risk factor associated with certain
types of risk cancer [7].
Since the link between Helicobacter pylori and gastric cancer was identified [8], the possible
links between the host and its microbiome, in terms of response, exacerbation or even the initi-
ation of carcinogenesis are receiving increased attention. Changes in the bacterial loads for key
species, for example, have been linked to oral squamous carcinoma, colorectal cancer and
oesophageal cancer [9]. Within the context of lung cancer, a link between H. pylori seropositiv-
ity and risk of lung cancer has been investigated through the use of serum samples from
patients with lung cancer and age-matched controls [10]. Although, no correlation was
reported, it did show that a number of people with lung cancer tested seropositive for H. pylori
and there is a possibility it could be present in the lung cancer microbiome. The use of serum
in this study highlights how the microbiome-cancer links have been investigated using cancers,
such as oral [11–14] and colorectal [15–17] where sampling can be minimally invasive. How-
ever, the enclosed nature of the lung complicates sample collection and has involved sampling
using bronchoalveolar lavage fluids (BAL), tissue from excised lungs obtained during trans-
plantation surgery [18], or indirectly through serum [10].
In our previous study, we have used sputum to suggest chemical biomarkers linked to lung
cancer. Sputum is a complex of mucus, microorganisms, cellular debris and other particles
trapped in the lungs by mucus. It provides a non-invasive method of obtaining upper bron-
chial tract samples that also involves minimal patient discomfort [19]. The production of spu-
tum is a symptom of inflammatory lung airway diseases such as lung cancer, COPD, asthma,
and cystic fibrosis, it is often used to provide insight into the underlying malignancies [20].
Indeed, conditions such as asthma [21], COPD [18, 22, 23] and cystic fibrosis [24] have used
microbial profiling techniques to reveal potentially important insights into the role that
microbes may play in disease aetiology, progression and treatment. Sputum from lung patients
has been used to explore, albeit in a culture-dependent method, the microbial flora and the
level of antibiotic resistance [25]. A further, culture-independent study using amplicon
sequencing suggested that, in sputum, there are significant differences between lung cancer
patients and controls, particularly within the Granulicatella, Abiotrophia, and Streptococcus
genera [26]. However, to date, there has been no study into the metagenomic composition of
the sputum microbiome in lung cancer. Therefore, resolution at the species level of taxonomy
has not been possible, and the functional capacity of the microbiome has not been investigated.
Other respiratory conditions have been studied with this method, such as cystic fibrosis,
though with relatively small sample numbers, such as two [27], five [28], and ten [29].
In this pilot-level study, we aimed to assess the potential clinical usefulness of using the spu-
tum microbiome as a non-invasive sampling medium by which biomarkers for lung cancer
status and stage could be obtained. By taking advantage of recent technological advances, that
have already been utilised in the human gut microbiome [30] that have reduced both the cost
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and complexity of metagenomic sequencing, we report on preliminary data that suggests sig-
nificant taxonomic and functional differences are present in the sputum microbiome of
patients with and without lung cancer. Furthermore, we identify the relative abundances of
Granulicatella adiacens, and six other bacterial species, Enterococcus sp. 130, Streptococcus
intermedius, Escherichia coli, Streptococcus viridans, Acinetobacter junii, and Streptococcus sp. 6,
as a potential, non-invasive and novel biomarker for lung cancer, and lung cancer progression.
Methods
Ethics statement
The MedLung observational study (UKCRN ID 4682) received loco-regional ethical approval
from the Hywel Dda Health Board (05/WMW01/75). All procedures undertaken were in
accordance with the ethical standards of the Helsinki Declaration (1964 and amended 2008) of
the World Medical Association. Written informed consent was obtained from all participants
at least 24 hours before sampling, at a previous clinical appointment, and all data was link
anonymised before analysis. All methods were carried out in accordance with relevant guide-
lines and regulations. The sponsor was Hywel Dda University Health Board and neither the
funders–Aberystwyth University or NISCHR—nor sponsor had any input into the design or
reporting of the study.
Patient recruitment and sampling
Spontaneous sputum was collected from ten clinical patients, who were referred for further
diagnostics at Prince Phillip Hospital, Llanelli, UK, after presentation with lung cancer-like
symptoms at their General Practice. Spontaneous sputum samples were taken before broncho-
scopic investigation for lung cancer diagnosis. All spontaneous sputum samples were con-
firmed as sputum, based on bronchial cell content, by a Consultant Pathologist in the Hywel
Dda University Health Board Pathology Service.
Isolation of genomic DNA
Spontaneous sputum samples were transferred, on dry ice, to Aberystwyth University labora-
tories, were they were thawed on ice for 60 minutes. Subsequently, samples were treated with 5
mL of 30% aqueous methanol and 500 μL of a methanol-dithiothreitol (DTT) solution, made
up by adding 2.5 g DTT to 31 mL of 30% aqueous methanol, and then vortex mixed for 15
minutes. Samples then underwent centrifugation at 1500 x g for ten minutes, and the superna-
tant removed. The remaining pellet was transferred to a PCR grade 1.5 mL microcentrifuge
tube. Genomic DNA was extracted from 100 μL of treated sputum using a FastDNA SPIN kit
for soil (MP Biomedical, Santa Ana, USA) following manufacturer’s instructions. Bead beating
was carried out in a FastPrep-24 machine (MP Biomedical) with three cycles at speed setting
6.0 for 30 seconds, with cooling on ice for 60 seconds between cycles. Genomic DNA was
eluted in to 30 μL of DES and dsDNA concentration determined using the Quant-iT dsDNA
High Sensitivity assay kit and a Qubit fluorometer (Life Technologies, Paisley, UK). All DNA
extractions were completed using the same FastDNA SPIN kit box to minimise the potential
effect of extraction kit contamination, as previously reported [31].
Metagenomic library preparation and sequencing
After extraction of genomic DNA, samples were normalised to 10 ng/μL with PCR grade
water (Roche Diagnostics Limited, West Sussex, UK) and 50 ng used to create metagenomic
libraries using the Nextera1 DNA kit (Invitrogen, San Diego, USA) following manufacturer’s
Microbiome biomarkers for lung cancer
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instructions, except that a MinElute PCR purification kit (Qiagen, Ltd Crawley, UK) was used
for the clean-up of tagmented DNA. Nextera1 DNA libraries were quantified using the
Quant-iT dsDNA High Sensitivity assay kit, and approximate library sizes determined by run-
ning on a 2% agarose gel alongside HyperLadder IV (Bioline, London, UK). Sample libraries
were pooled in equimolar concentrations and sequenced at 2 x 151 bp using an Illumina
HiSeq 2500 rapid run, with samples duplicated over two lanes, and following standard manu-
facturer’s instructions at the IBERS Aberystwyth Translational Genomics Facility.
Metagenomic sequence analysis
After sequencing, output files for each lane were combined into one file, using the BioLinux 7
environment [32], for each read direction. Sequencing files were uploaded to MG-RAST
(v3.2) [33] as FASTQ files. Paired-end reads were joined using the facility available within
MG-RAST, with non-overlapping reads retained. Sequences were dereplicated and dynami-
cally trimmed using the default parameters for FASTQ files, and human sequences removed
by screening against the Homo sapiens (v36) genome, available via NCBI. The MG-RAST pipe-
line used an automated BLASTX annotation of metagenomic sequencing reads against the
SEED non-redundant database [34]. SEED matches can be matched to identity at various taxo-
nomic levels; including genus and species levels. Organism abundances were modelled and
exported from MG-RAST using the ‘Best Hit Classification’ after alignment to the M5NR data-
base, with alignment cut-off parameters set at an e-value maximum of 1 x 10−5, a minimum
identity of 97%, and a minimum alignment of 15. Functional abundances were modelled
and exported from MG-RAST using ‘Hierarchical Classification’. SEED matches can also be
related to metabolic information, again at different levels of classification. The coarsest level of
organization; the generalized cellular function was termed level 1, and the finest, individual
subsystems level 3. To normalise for potential variations in sequencing efficacy, sequence
abundances were transformed into percentages based upon the total read abundance for each
sample at each taxonomic or functional level. Statistical analysis was completed using the
MetaboAnalyst 2.0 [35] facility and MINITAB 14 package. Multiple hypotheses testing was
not corrected for during statistical analyses. Sequence files can be viewed on MG-RAST via the
IDs listed in S1 Table and raw sequence reads, after removal of host DNA, have been deposited
at the European Nucleotide Archive under study primary accession number PRJEB9033 and
secondary accession number ERP010087.
16S rRNA quantitative PCR
Quantitative PCR was completed on neat extracted DNA against standards created through
amplification of the 16S rRNA gene of five randomly selected samples (three LC- and two
LC+), as previously described [36]. Subsequent qPCR reactions were completed in 25 μL reac-
tion volumes, consisting of 1X SYBR Green Mastermix (Life Technologies), 400 nM of each of
the forward and reverse primers, and 1 μL of neat DNA extract, with the reaction volume
being made up with PCR grade water (Roche Diagnostics Limited, West Sussex, UK). Reac-
tions were run using a C100 thermal cycler (BioRad, Hercules, USA) and CFX96 optical detec-
tor (BioRad), with data captured using CFX Manager software (BioRad), under conditions of
95˚C for 10 minutes, 40 cycles of 95˚C for 15 seconds and 60˚C for 60 seconds, followed by a
melt curve consisting of a temperature gradient of 60˚C to 95˚C in 0.5˚C increments, each for
5 seconds.
Microbiome biomarkers for lung cancer
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Results
After histological investigation of the ten patients referred with lung cancer-like symptoms,
four patients were diagnosed with lung cancer (one squamous cell NSCLC, one adenocarci-
noma NSCLC, one large cell carcinoma NSCLC, and one where a bronchoscopy was not possi-
ble and a radiological diagnosis was required), and six were found to be negative for lung
cancer presence. Summarised patient information is shown in Table 1, and full individual
patient information in S1 Table, with no discernible differences between the two patient
groups being observed. Of particular importance, no significant (P = 0.197) differences were
observed between smoking pack years of either LC group. DNA extractions for LC+ groups
were a mean of 83.28 ng/μL and for LC- were 91.42 ng/μL, with no significant (P = 0.786) dif-
ferences evident between groups. Sequencing statistics, both pre and post and quality control
process are summarised in S2 Table, alongside corresponding one-way ANOVA P values. In
all but one of the sequencing statistics, “identified rRNA features”, no significant differences
were present, suggesting that the HiSeq 2500 sequencing platform and subsequent bioinfor-
matic analysis using MG-RAST did not introduce any level of bias which may affect results
interpretation. Additionally, no significant difference was observed between the bacterial loads
of the two groups, based on estimated 16S rRNA copy number (P value = 0.616), data not
shown, nor between the alpha diversity measures of species richness between samples, 1
(P value = 0.778). (Fig 1).
At the species level of taxonomy (Fig 2A), and at level 3 of functional classifications (Fig
2C), principal component analysis, created using normalised bacterial species abundance was
suggestive that the presence of a malignancy within the lungs does not change either the taxo-
nomic composition or the functional capacity of the sputum microbiome on a substantial
Table 1. Average patient characteristics for negative and positive lung cancer groups. Data are
means for either the negative or the positive lung cancer groups. Standard deviations, where appropriate, are
given in brackets. FEV1% of predicted is forced expulsion volume of lungs in one second, as a percentage of
the predicted value for that patient. CO level is carbon monoxide in parts per million concentration. P Value
column indicates value from one-way ANOVA analysis.
LC- LC+ P Value
Number 6 4 N/A
Age 58.8 (14.8) 73.3 (7.2) 0.112
Gender
Male 4 2 N/A
Female 2 2 N/A
Smoking Status
Current 4 3 N/A
Ex 2 0 N/A
Never 0 1 N/A
Smoking Pack Years 57.7 (35.4) 28.8 (24.6) 0.197
Infection Present
Yes 0 0 N/A
No 6 4 N/A
Antibiotic Use
Yes 1 0 N/A
No 5 4 N/A
CO Level (ppm) 21.0 (24.5) 7.3 (8.0) 0.317
FEV1% of Predicted 77.1 (22.3) 69.3 (16.0) 0.559
https://doi.org/10.1371/journal.pone.0177062.t001
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Fig 1. Alpha diversity group means. Alpha diversity measures of species richness, as calculated by the MG-RAST analysis pipeline, show no
significant difference between either positive or negative lung cancer groups. This suggests that any changes to the lung microbiome as a result of a
malignancy are not large-scale community shifts.
https://doi.org/10.1371/journal.pone.0177062.g001
Microbiome biomarkers for lung cancer
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scale. However, more subtle changes in individual bacterial species or functional classifications
may be evident which could have utility as disease biomarkers.
As metagenomic sequencing is able to resolve to the species level of taxonomy, the ‘core’
microbiome of both negative and positive lung cancer patients was investigated (Table 2), as
Fig 2. Principal component analysis of taxonomic and functional classifications. PCA plots and biplots, to identify factors leading to
observed groupings, created using the MetaboAnalyst platform using normalised percentage abundance of (A and B) bacterial species and (C and
D) level 3 functional alignments. LC- samples are indicated by red symbols and LC+ by green symbols. Coloured areas indicate 95% confidence
intervals of PCA groupings as calculated by MetaboAnalyst. For biplots, red-letter annotations show the factor contributing to the observed
separation.
https://doi.org/10.1371/journal.pone.0177062.g002
Microbiome biomarkers for lung cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0177062 May 25, 2017 7 / 17
this is likely to give greater insight into the microbiome than a genus level profile. A total of
seven species were found to be present in all ten samples, with Streptococcus viridans found to
be significantly (P = 0.042) higher in the positive lung cancer samples. Six further species were
found to be present in all of the LC- but not all of the LC+ samples, but due to their variation
within the LC- group were significantly different in their level of abundance. However, a total
of 16 bacterial species were found in all of the positive lung cancer samples, but not all of the
LC- samples, with Granulicatella adiacens (P = 0.015), Streptococcus intermedius (P = 0.023),
and Mycobacterium tuberculosis (P = 0.036) significantly higher in the LC+ group.
Additionally, at the taxonomic level, significant (t-Test P< 0.05) fold changes in regards to
species abundance between positive and negative lung cancer cases were identified (Fig 3).
This reflected differences in the ‘core’ microbiome changes shown in Table 2, namely
Table 2. Average percentage abundance of species present in ‘core’ microbiome. Average percentage abundance of species present in the negative
and positive lung cancer groups, with corresponding P values from one-way ANOVA. % column shows average abundance, St. Dev. column shows standard
deviation, and Count column shows the number of patients in each group in which the species was found, out of the total number of patients. The top division
represents species present in all samples, the second division those found in all negative samples, and the bottom division those found in all positive samples.
Species LC- LC+ P Value
% St. Dev. Count % St. Dev. Count
Found in all samples
Streptococcus viridans 0.02% 0.01% 6 / 6 0.10% 0.04% 4 / 4 0.042
Streptococcus thermophilus 1.73% 1.33% 6 / 6 5.96% 2.51% 4 / 4 0.115
Ochrobactrum anthropi 0.48% 0.20% 6 / 6 0.95% 0.32% 4 / 4 0.188
Streptococcus pneumoniae 7.30% 1.84% 6 / 6 15.17% 6.72% 4 / 4 0.200
Enterococcus faecalis 0.10% 0.03% 6 / 6 0.25% 0.13% 4 / 4 0.203
Salmonella enterica 0.01% <0.01% 6 / 6 0.05% 0.04% 4 / 4 0.271
Neisseria meningitidis 1.04% 0.73% 6 / 6 0.79% 0.30% 4 / 4 0.756
Found in all LC- samples
Escherichia coli 0.01% 0.01% 6 / 6 0.06% 0.04% 3 / 4 0.207
Fusobacterium nucleatum 0.16% 0.14% 6 / 6 <0.01% <0.01% 2 / 4 0.310
Haemophilus influenzae 22.29% 17.38% 6 / 6 4.30% 3.70% 3 / 4 0.346
Streptococcus parasanguinis 9.87% 4.24% 6 / 6 4.75% 4.75% 1 / 4 0.398
Streptococcus pyogenes 0.24% 0.11% 6 / 6 0.31% 0.12% 3 / 4 0.659
Veillonella parvula 1.60% 0.64% 6 / 6 2.01% 1.84% 2 / 4 0.805
Found in all LC+ samples
Granulicatella adiacens <0.01% <0.01% 1 / 6 0.07% 0.03% 4 / 4 0.015
Streptococcus intermedius <0.01% <0.01% 2 / 6 0.06% 0.02% 4 / 4 0.023
Mycobacterium tuberculosis <0.01% <0.01% 5 / 6 0.01% <0.01% 4 / 4 0.036
Enterococcus sp. 130 0.01% 0.01% 5 / 6 0.06% 0.02% 4 / 4 0.050
Streptococcus sp. 6 0.01% 0.01% 5 / 6 0.06% 0.02% 4 / 4 0.050
Acinetobacter junii 0.01% <0.01% 5 / 6 0.03% 0.01% 4 / 4 0.112
Streptococcus salivarius 0.14% 0.10% 4 / 6 3.23% 2.46% 4 / 4 0.195
Shewanella sp. <0.01% <0.01% 3 / 6 0.01% <0.01% 4 / 4 0.206
Streptococcus vestibularis 0.01% 0.01% 5 / 6 1.31% 0.74% 4 / 4 0.208
Lactobacillus paracasei <0.01% <0.01% 1 / 6 2.61% 2.60% 4 / 4 0.234
uncultured bacterium <0.01% <0.01% 4 / 6 <0.01% <0.01% 4 / 4 0.266
Lactococcus lactis 0.02% 0.01% 4 / 6 0.02% 0.01% 4 / 4 0.379
Neisseria gonorrhoeae 0.29% 0.20% 5 / 6 0.17% 0.08% 4 / 4 0.500
Rhodococcus erythropolis 0.09% 0.11% 3 / 6 0.13% 0.06% 4 / 4 0.628
Stenotrophomonas maltophilia 0.10% 0.05% 5 / 6 0.20% 0.08% 4 / 4 0.662
Staphylococcus aureus 0.42% 0.49% 5 / 6 0.20% 0.14% 4 / 4 0.666
https://doi.org/10.1371/journal.pone.0177062.t002
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significantly higher abundances of G. adiacens, S. intermedius, and M. tuberculosis, in positive
cases, with additional significant increases evident in the abundance of Streptococcus viridans
and Mycobacterium bovis.
Significant fold changes in functional alignments were also identified. At the crudest level
of functional classification, Level 1, no differences were evident. However, at Levels 2 and 3
(Fig 4), significant differences were observed. At Level 2, four functional classifications were
higher in positive lung cancer samples. At Level 3, seven functional classifications were higher
in positive lung cancer samples, whilst three were lower, when compared to negative lung can-
cer samples. These differences appeared to be across a wide range of biological functions.
To evaluate the potential of using metagenomics to identify novel biomarkers for lung can-
cer and lung cancer progression, both a species level (S3 Table) and Level 3 functional regres-
sion analyses (S4 Table) were completed. Those regressions with an R2 value of 80% (chosen as
an arbitrary cut-off; data not shown for regressions with R2 below 80%) or more were plotted
to identify those with differing relationships between negative and positive lung cancer groups.
From this method of analysis, G. adiacens was identified as having positive correlations
(P value of regression relationship less than 0.001 in all instances) with six other bacterial spe-
cies (Fig 5) in positive lung cancer samples, but not in negative lung cancer samples. Addition-
ally, when LC+ cancer stages were plotted against targeted bacterial abundance, a pattern with
disease progression was observable. Although suggestive that relative abundances of some
Fig 3. Significant fold changes in species abundance from negative to positive for lung cancer. Using the online features of MetaboAnalyst 2.0,
significant fold changes, as determined by t-Tests with P values <0.05, were identified. Five species, from three genera, were all higher in positive lung
cancer samples, with Granulicatella adiacens and Streptococcus intermedius showing the highest change.
https://doi.org/10.1371/journal.pone.0177062.g003
Microbiome biomarkers for lung cancer
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bacterial species could indicate lung cancer progression, this will require confirmation with a
larger cohort of patient samples.
Discussion
The role of the microbiome in a range of respiratory conditions has been well documented;
however, lung cancer has received only minimal attention. The lung cancer microbiome has
been detailed, at the genus level, in female non-smokers from Xuanwei, China, through the
use of amplicon sequencing. Interestingly, significant differences were only detected between
sputum samples, and not buccal samples, suggesting a localised effect in the bronchial tree of
the lung [26]. This study suggested a potential role of household coal burning exposure, and its
effect on the lung microbiome in patients with lung cancer, rather than tobacco smoking,
which is the most common cause of lung cancer in more economically developed countries
Fig 4. Significant fold changes in levels 2 and 3 functions from negative to positive lung cancer. Using MetaboAnalyst 2.0, significant fold
changes of Level 2 (grey bars) and 3 (black bars) functional alignments, as determined through t-Tests with P values <0.05, were identified. A total
of four Level 2 functional alignments were higher in positive lung cancer, alongside seven Level 3 functions. Three Level 3 functional alignments
were lower in positive lung cancer samples.
https://doi.org/10.1371/journal.pone.0177062.g004
Microbiome biomarkers for lung cancer
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Fig 5. Regression analysis suggests importance of G. adiacens in positive lung cancer samples.
Species regression analyses were completed, and those with an R2 value of greater than 80% were plotted to
identify differing relationships between negative and positive lung cancers. This type of relationship was
shown to exist between G. adiacens and six other species, with a strong positive relationship present in
positive lung cancer samples, and no correlation evident within negative lung cancer samples. Normalised
percentage abundances are shown on x and y axes.
https://doi.org/10.1371/journal.pone.0177062.g005
Microbiome biomarkers for lung cancer
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[37]. In this pilot-level study, we looked to address this, and to develop a more in-depth view
of the microbiome with clinically relevant samples.
Through the use of metagenomic sequencing, we have identified a number of bacterial spe-
cies that are increased in abundance in patients with lung cancer, than in those without. Fur-
thermore, we have also identified G. adiacens as having a significant positive relationship with
six other bacterial species, Enterococcus sp. 130, Streptococcus intermedius, Escherichia coli,
Streptococcus viridans, Acinetobacter junii, and Streptococcus sp. 6. This significant correlation
is only observed in patients positive for lung cancer. The Granulicatella genus has been identi-
fied as being significantly higher in the sputum of non-smoking lung cancer cases [26], sug-
gesting that it may be a true reflection of lung cancer state, rather than a by-product of tobacco
smoking. The Granulicatella genus, and G. adiacens specifically, is a difficult organism to cul-
ture, which may be the limiting factor that explains the minimal study that has been conducted
into it [38]. It has however, been associated with endocarditis [39] and septicaemia [40]. The
sputum microbiome is an understudied area within respiratory microbiology. This may be
surprising given that the production of sputum is typically a symptom of lung dysfunction but
may reflect the fact that comparison to ‘healthy’ samples is difficult. This stated, many of the
bacterial genera and species that we identified in the LC- patients have also been reported in
previous studies investigating changes in the sputum microbiome associated with lung disease
[26, 41]. This suggests that our observations are robust and represent an accurate reflection of
the bacterial composition of the lung microbiome.
The changes in G. adiacens, as a commensal bacterium and an opportunistic human patho-
gen, seem likely reflect a change in an “ecological” niche, such as in sputum composition [42],
within the lungs of patients with lung cancer. Of the six other bacterial species associated with
G. adiacens in LC+ patients, none appear to have been previously linked to lung cancer in the
literature. They may also be responding to a changes in the cancerous lung, or potentially,
exist in a synergistic relationship with G. adiacens which enables their higher abundance.
Regardless of the biological basis for these significantly higher abundances seen, they neverthe-
less have the potential to act as biomarkers for lung cancer, in regards to both lung cancer sta-
tus, but also in staging, due to the pattern of abundances seen in Fig 5. Clearly, given the small
scale nature of this pilot study, albeit large for metagenomic studies, these findings should only
be taken as suggestive. For example, it is possible that false positives are reported as a result of
multiple hypotheses testing in the correlation analyses. Furthermore, due to the limited study
size, we were unable to separate our patient cohort into individual test and validation cohorts–
which is the ‘gold’ standard for biomarker discovery studies. We were also limited in the statis-
tical tests that could be performed such as controlling for multiple hypothesis testing and non-
parametric analysis. These points stated, it is highly relevant that our findings were still in line
with previously reported studies identifying members of the Granulicatella genus as biomark-
ers for lung cancer status, thereby implying the veracity of our results. Validation of the bacte-
rial species identified in this study, primarily G. adiacens, as potential biomarkers of lung
cancer status and stage must be completed in larger cohorts which possess sufficient statistical
power to allow for true sensitivity and specificity rates to be calculated.
Crucially, metagenomic sequencing allows the field of microbiomics to move beyond char-
acterising the microbiome simply in terms of its taxonomic composition, and more towards
understanding how its functional capability shifts in response to disease state. Here we have
found a total of four Level 2 classifications that are significantly higher in patients positive for
lung cancer, including those involved in arginine use, urea cycle, putrescine and gamma-ami-
nobutyric acid (GABA) utilisation, and invasion and intracellular resistance. Interestingly, ele-
vated levels of polyamines, such as putrescine and GABA, been associated with a range of
cancers including lung malignancies [43]. Polyamines offer a rich nitrogen source of bacteria,
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and elevated levels associated with lung cancer could explain why there are significantly more
associated alignments in positive lung cancer cases. At Level 3 of functional classification,
seven functions were significantly higher, and three significantly lower, in the positive lung
cancers. Some of these increases reflected Level 2 changes, but others, such as higher levels of
iron siderophore sensors and receptor system alignments, further suggest that changes in the
cancerous lung are reflected by changes in the lung microbiome. Elevated iron levels are asso-
ciated with lung cancer [44], and as iron is essential for many cellular functions in bacteria, it
is not unexpected that elevated levels of iron associated with lung cancer would result in a
selective pressure to reflect this in the microbiome. Functional changes are not unexpected in
the lung microbiome as a response to malignancy formation, but this study is the first to con-
firm that such synergy exists. This suggests that a systems biology approach towards studying
the lung microbiome is required to better understand this relationship.
An emerging issue within microbiome research is that of contaminated DNA extraction kit
and reagents which has the potential to impact both 16S rRNA amplicon and shotgun metage-
nomic studies. This appears to be of substantial importance when assessing microbial commu-
nities of low biomass [31]. Within this body of work, no significant differences in terms of
DNA extraction concentrations were observed between LC status groups. Furthermore, the
DNA extraction concentration suggests that the sputum microbiome is not one with a low bio-
mass, and thus unlikely to be affected by issues of contaminated DNA extraction kits and
other reagents.
Our use of spontaneous sputum is a well-established diagnostic medium for lung cancer
because of its non-invasive collection, and because it is symptomatic of lung cancer as a dis-
ease. Therefore, it offers a viable alternative to radiography based diagnoses for high-through-
put, non-invasive, and low-risk screens [45]. However, it should be appreciated that sputum
production is localised to the upper bronchial tract, and particularly the bronchial tree. As
microbiome studies in other respiratory diseases have shown, including in COPD [18] and
cystic fibrosis [24], spatial differences can exist within the lungs and therefore, sputum should
only be taken as representative of the microbiome in the upper bronchial tract. Furthermore,
the microbiome present within sputum samples is likely to consist of a number of taxa present
within the oral cavity, which may be present at orders of magnitude greater than those taxa
with are present within the lower respiratory tract. Although this may impair the potential
insight into the lung microbiome gained through the use of sputum, it does not exclude it as a
viable sample medium to be used in screening for lung cancer.
Conclusions
This novel pilot-level study has expanded upon our knowledge of the microbiome in patients
with lung cancer, using clinically relevant control samples, particularly in regards to the func-
tional capacity of the microbiome, and its taxonomic composition at the species level. Addi-
tionally, we have demonstrated the strength of using metagenomics to identify potential
biomarkers for disease state and progression, namely G. adiacens and its correlations in abun-
dance with a range of bacterial species, which could have clinical use. However, due to the
small sample number in this pilot study, more work is needed to confirm these suggestive rela-
tionships, and whether they are observable in earlier stage lung cancers, and whether they are
able to differentiate between different LC histology.
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